{"id":"celecoxib-esomeprazole","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal upset"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Celecoxib works by blocking the action of COX-2 enzymes, which are involved in the production of prostaglandins that cause inflammation and pain. Esomeprazole, on the other hand, works by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby reducing gastric acid secretion.","oneSentence":"Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing inflammation and pain. Esomeprazole is a proton pump inhibitor that reduces stomach acid production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:16.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT05215236","phase":"NA","title":"Opiate Sparing Protocol Randomized Controlled Trial in Open Distal Radius Fracture Repair","status":"COMPLETED","sponsor":"Campbell Clinic","startDate":"2022-03-01","conditions":"Distal Radius Fracture","enrollment":72},{"nctId":"NCT04294680","phase":"NA","title":"Opiate Sparing Versus Opiate Based Following Shoulder Arthroplasty","status":"COMPLETED","sponsor":"Campbell Clinic","startDate":"2019-08-01","conditions":"Shoulder Surgery","enrollment":82},{"nctId":"NCT03625050","phase":"PHASE2","title":"Efficacy and Safety of Chuna Manual Treatment as an Adjunctive Therapy After Total Knee Arthroplasty: A Study Protocol for a Single-Center, Randomized, Assessor Blind, Parallel-Group Clinical Trial","status":"COMPLETED","sponsor":"Gachon University Gil Oriental Medical Hospital","startDate":"2018-11-01","conditions":"Total Knee Replacement, Manipulation","enrollment":22},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT00153660","phase":"PHASE3","title":"Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2005-06","conditions":"Arthritis, Cardiovascular Diseases, Cerebrovascular Disorders","enrollment":514},{"nctId":"NCT02307305","phase":"PHASE2","title":"Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2014-08","conditions":"Neuropathic Pain","enrollment":168},{"nctId":"NCT02355236","phase":"PHASE4","title":"Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis","status":"UNKNOWN","sponsor":"Severance Hospital","startDate":"2015-02","conditions":"Osteoarthritis","enrollment":106},{"nctId":"NCT00473980","phase":"PHASE4","title":"Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Göteborg University","startDate":"1998-12","conditions":"Colorectal Cancer","enrollment":28},{"nctId":"NCT00664560","phase":"PHASE3","title":"Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-04","conditions":"Osteoarthritis","enrollment":614},{"nctId":"NCT00665431","phase":"PHASE3","title":"Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-04","conditions":"Osteoarthritis","enrollment":610},{"nctId":"NCT00365313","phase":"PHASE3","title":"Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2002-08","conditions":"Arthritis, Bleeding Ulcer","enrollment":273}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"celecoxib, esomeprazole","genericName":"celecoxib, esomeprazole","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing inflammation and pain. Esomeprazole is a proton pump inhibitor that reduces stomach acid production. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}